SS
Silvia  Stacchiotti
Highly rated in
29
conditions
Highly rated in
29
conditions
Check Silvia Stacchiotti's experience treating your condition:
About Silvia Stacchiotti

Silvia Stacchiotti practices in Milano, Italy. Stacchiotti is highly rated in 29 conditions, according to our data. Her top areas of expertise are Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Alveolar Soft Part Sarcoma, and Synovectomy.

Her clinical research consists of co-authoring 217 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Locations
Milano, 20133, IT
Background & Education
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
View 9 Less Clinical Trials -

Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more